Please ensure Javascript is enabled for purposes of website accessibility

Dow Jones Recovers 1,300 Points Despite Increase in U.S. Coronavirus Deaths

By Mark Prvulovic - Mar 2, 2020 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The markets witnessed a major recovery on Monday. Will it last?

Financial markets jumped substantially on Monday, recovering partially from the significant losses seen last week. The Dow Jones Industrial Average is up 1,294 points, or 5%, while the S&P 500 and the Nasdaq are up 4.6% and 4.5% respectively.

Today's performance marks a major turnaround from last week, when all three major U.S. stock market indexes lost over 10% of their value in what was the worst five-day trading session since 2008. The main cause of last week's losses was due to the continued spread of the coronavirus outbreak, which saw an alarming number of COVID-19 infections in non-Asian countries, namely Italy and Iran.

A person drawing a rising chart on a chalkboard.

Image source: Getty Images.

Monday's stock market surge also seems to be unaffected by the growing number of COVID-19 deaths in the U.S. News broke this morning that the number of deaths had grown from just one on Friday to six. All of these cases were in Washington state, leading health authorities to worry that further outbreaks on the West coast are on the horizon.

The government's response

In response to the growing crisis, President Trump said he asked pharmaceutical companies to speed up work on potential COVID-19 treatments. The president, alongside other members of his administration, met with several executives from major healthcare firms on Monday.

At the moment, only two companies have COVID-19 treatments in clinical testing. The first is Gilead Sciences' (GILD 0.89%) remdesivir, a former Ebola drug that's shown to be effective in treating COVID-19 symptoms. The other is an mRNA-based vaccine developed by Moderna (MRNA 4.97%).

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.36 (0.89%) $0.55
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.